Effects of BPC-157 and TB-500 on Achilles tendon healing in rats: A histopathological and biomechanical study.
TB-500 showed a significant biomechanical advantage in Achilles tendon healing in rats, while BPC-157 did not demonstrate statistically significant improvements. Further studies are needed to explore their potential in human tendon repair.
Where it sits
this study against the rest of the thymosin alpha-1 corpusSummary and findings
This study evaluated the effects of BPC-157 (10 µg/kg/day) and TB-500 (60 µg/kg/day) on Achilles tendon healing in 32 male Sprague-Dawley rats. The treatments were administered intraperitoneally for four weeks following tendon transection and repair, with biomechanical and histopathological assessments conducted at the end of the treatment period. Both peptides showed improvements in tendon healing parameters, with TB-500 demonstrating significant biomechanical advantages.
Abstract
<h4>Objectives</h4>This study aims to evaluate the effects of BPC-157, synthetic thymosin beta-4 (TB-500), and their combination on Achilles tendon healing using biomechanical, histopathological, histochemical, and immunohistochemical analyses in a rat model.<h4>Materials and methods</h4>Thirty-two male Sprague-Dawley rats, each aged 12 weeks and weighing approximately 330 g, underwent standardized Achilles tendon transection and repair and were randomly assigned to four groups, with eight rats in each group: control, BPC-157 (10 µg/kg/day), TB-500 (60 µg/kg/day), and combined BPC-157 + TB-500 (BPC + TB). Treatments were administered intraperitoneally for four weeks postoperatively. At four weeks, tendons were harvested for biomechanical testing or histological evaluation. Maximum load to failure was assessed biomechanically. Histological and histochemical analyses included hematoxylin-eosin, Masson trichrome, Alcian blue, and Sirius red staining and were evaluated using Bonar and Movin scoring systems. Expression of collagen types I and III was assessed immunohistochemically and semiquantified using H-score analysis.<h4>Results</h4>Biomechanical testing revealed higher maximum load to failure values in the BPC-157 and TB-500 groups compared to controls, reaching statistical significance in the TB-500 group (p < 0.05). Histopathological evaluation demonstrated significantly lower total Bonar scores in the TB-500 group (p = 0.016) and significantly lower total Movin scores in the TB-500 and BPC + TB groups (p = 0.017 and p = 0.040, respectively) relative to controls, indicating improved tendon architecture, collagen alignment, and reduced degenerative changes. The BPC-157 group showed numerically lower scores without reaching statistical significance for total scores. Sirius red birefringence analysis showed increased type I collagen organization and altered type III collagen distribution in treatment groups, particularly in the TB-500 group, suggesting progression toward matrix maturation. Immunohistochemical analysis revealed no significant differences in collagen type I expression among groups, whereas collagen type III expression differed significantly, consistent with histochemical findings. Combined BPC-157 and TB-500 treatment did not confer additional benefits compared to either agent alone.<h4>Conclusion</h4>In this exploratory rat model study, both BPC-157 and TB-500 were associated with improved histopathological parameters and extracellular matrix organization during early Achilles tendon repair, with TB-500 additionally demonstrating a significant biomechanical advantage at four weeks. The absence of additive effects with combination therapy may reflect convergence on shared downstream pathways; however, this hypothesis requires further experimental confirmation. These preliminary findings indicate that both peptides warrant further investigation as candidate adjuncts to tendon repair, pending dose-optimization and longer-term studies.
Background
This study addresses the biological question of how BPC-157 and TB-500 influence Achilles tendon healing, building on existing knowledge of their roles in tissue repair. Prior research has indicated potential benefits of these peptides in various healing contexts, but their specific effects on tendon healing had not been thoroughly examined. Understanding their impact could inform future therapeutic strategies for tendon injuries.
Methods
The study utilized a randomized controlled design involving 32 male Sprague-Dawley rats, aged 12 weeks and weighing approximately 330 g. The rats underwent standardized Achilles tendon transection and repair, followed by random assignment to four treatment groups: control, BPC-157 (10 µg/kg/day), TB-500 (60 µg/kg/day), and combined BPC-157 + TB-500. Treatments were administered intraperitoneally for four weeks, with biomechanical and histopathological evaluations conducted post-treatment.
Results
The primary endpoint revealed that the TB-500 group had a higher maximum load to failure compared to controls (p < 0.05). Histopathological evaluations showed significantly lower total Bonar scores in the TB-500 group (p = 0.016) and lower total Movin scores in both the TB-500 (p = 0.017) and BPC + TB (p = 0.040) groups. The BPC-157 group exhibited numerically lower scores without statistical significance. Immunohistochemical analysis indicated significant differences in collagen type III expression among groups.
Interpretation
These findings suggest that TB-500 may offer a significant biomechanical advantage in tendon healing, while BPC-157's effects were not statistically significant. The lack of additive benefits from the combination therapy indicates that both peptides may act on similar pathways. However, the small sample size and rodent model limit the applicability of these results to human contexts, necessitating further investigation.
Key findings
- Higher maximum load to failure in the TB-500 group compared to controls, p < 0.05.
- Total Bonar scores were significantly lower in the TB-500 group, p = 0.016.
- Total Movin scores were significantly lower in the TB-500 group (p = 0.017) and BPC + TB group (p = 0.040) compared to controls.
- BPC-157 group showed numerically lower scores for total scores without statistical significance.
- Collagen type III expression differed significantly among groups, consistent with histochemical findings.
Limitations
- small n=32
- rodent model, not human data
- short follow-up of four weeks
- no blinding reported
- no significant additive effects observed with combination therapy